ClinicalTrials.Veeva

Menu
C

Compass Oncology | Vancouver, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

MSB0011359C
Demcizumab
Platinum
M7824
Carboplatin
Osimertinib
NUC-3373
Lazertinib
Amivantamab
Nilotinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Carboplatin

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Active, not recruiting
Non-Squamous Non-small Cell Lung Cancer
Drug: Placebo Injection
Drug: Ivonescimab (SMT112 or AK112) Injection

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Active, not recruiting
Non-Squamous Non-small Cell Lung Cancer
Drug: Placebo Injection
Drug: AK112 Injection

A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who sta...

Active, not recruiting
Chronic Myeloid Leukemia
Drug: nilotinib

Trial sponsors

Akeso logo
Janssen (J&J Innovative Medicine) logo
Merck KGaA (EMD Serono) logo
Novartis logo
N
O
Pharmacyclics logo
Summit Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems